Bio-Path Holdings
BPTH

$1.77

0.24%

Market Cap: 3.68M

About: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2.03% less ownership

Funds ownership: 4.84% [Q4 2023] → 2.8% (-2.03%) [Q1 2024]

47% less funds holding

Funds holding: 19 [Q4 2023] → 10 (-9) [Q1 2024]

72% less capital invested

Capital invested by funds: $276K [Q4 2023] → $78.6K (-$198K) [Q1 2024]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 9

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 10

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$20

1,030%

upside

Avg. target

$33

1,783%

upside

High target

$40

2,160%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Roth MKM Philip Shen	1,030%upside $20	Buy Reiterated	8 Jul 2024
Roth MKM Philip Shen	2,160%upside $40	Buy Reiterated	18 Apr 2024
Roth MKM Jonathan Aschoff	2,160%upside $40	Buy Maintained	27 Mar 2024

See Analyst Rankings

Financial journalist opinion

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update on the Company's clinical progress and plans for expansion. “The Bio-Path team continues to work diligently toward advancing our important clinical work and have made meaningful progress in a number of areas critical to each program's success,” said Peter H.

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Why Is Bio-Path (BPTH) Stock Up 20% Today?

Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company's Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax.

Why Is Bio-Path (BPTH) Stock Up 20% Today?

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A warrants expire five years from the date of issuance and the short-term series B warrants expire twenty-four months from the date of issuance.

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024. To view the full announcement, including downloadable images, bios, and more, click here.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript

Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2024 Earnings Conference Call.

Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript

Bio-Path Holdings Reports First Quarter 2024 Financial Results

Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.

Bio-Path Holdings Reports First Quarter 2024 Financial Results

See News Rankings